Impact of the Puncture of the RP6 Point on the Ampliation and Injuries of the Perineum During Childbirth (PELVPUNCTURE)

October 15, 2019 updated by: Centre Hospitalier Sud Francilien

During the study period, any patient who enters labour and reports to the maternity ward and meets the inclusion and non-inclusion criteria is offered to participate in the study by the midwife acupuncturist present.

After signing the informed consent, a numbered envelope with the randomization arm is assigned to the patient. The acupuncturist midwife does not perform the delivery herself. At the time of the expulsive efforts, she punctures the point drawn at random. The patient's participation in the study ends when she leaves the labour room after the birth.

Study Overview

Detailed Description

During the study period, any patient who enters labour and reports to the maternity ward and meets the inclusion and non-inclusion criteria is offered to participate in the study by the midwife acupuncturist present. She's responsible for explaining the purpose and practicalities of the study orally and issues a written information document. The information provided is the same regardless of the midwife present. If she agrees to participate in the study, the patient signs the consent form.

After signing the informed consent, a numbered envelope with the randomization arm is assigned to the patient. The acupuncturist midwife does not perform the delivery herself. At the time of the expulsive efforts, she punctures the point drawn at random. She collects the clinical Research Form from the time the patient signs the consent form until she leaves the labour room after the birth.

The patient's participation in the study ends when she leaves the labour room after the birth. No further follow-up is planned.

Study Type

Interventional

Enrollment (Actual)

350

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Corbeil-Essonnes, France, 91106
        • Centre Hospitalier Sud Francilien

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • primiparous or multiparous women who have never given birth vaginally
  • term patients (after 37 weeks of amenorrhea)
  • patients delivering a fetus in cephalic presentation
  • patients speaking and understanding French.

Exclusion Criteria:

  • patients suspected of having a fetal macrosomy (greater than the 97th percentile) on the last ultrasound
  • patients with twin pregnancies
  • excised patients
  • patient who has made an acupuncture preparation during pregnancy
  • patients with fetal death in utero
  • patients requiring medical termination of pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: puncture of the RP6 point
The acupuncturist midwife, who does not perform the delivery herself, punctures the RP6 point at the time of the expulsive efforts.
Puncture of RP6 "San Yin Jiao" point, located just behind the posterior edge of the tibia 3 cm above the end of the inner malleolus.
PLACEBO_COMPARATOR: puncture of the placebo point
The acupuncturist midwife, who does not perform the delivery herself, punctures the placebo point at the time of the expulsive efforts.
Puncture of a placebo point "outside the meridian", with no effect

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of intact perineum after childbirth
Time Frame: immediately after childbirth
Rate of intact perineum after childbirth
immediately after childbirth

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of simple perineal tears
Time Frame: immediately after childbirth
lesion of the skin, vaginal mucosa, connective tissue, or sometimes the superficial muscle plane
immediately after childbirth
Rate of complete perineal tears
Time Frame: immediately after childbirth
Sphincter damage to the anus
immediately after childbirth
Rate of complicated complete perineal tears
Time Frame: immediately after childbirth
Damage to the anal mucosa
immediately after childbirth
Rate of episiotomies performed
Time Frame: immediately after childbirth
Rate of episiotomies performed
immediately after childbirth

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Berangère BC CANON, MD, Centre Hospitalier Sud Francilien

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 4, 2019

Primary Completion (ACTUAL)

July 1, 2019

Study Completion (ACTUAL)

July 1, 2019

Study Registration Dates

First Submitted

October 14, 2019

First Submitted That Met QC Criteria

October 15, 2019

First Posted (ACTUAL)

October 16, 2019

Study Record Updates

Last Update Posted (ACTUAL)

October 16, 2019

Last Update Submitted That Met QC Criteria

October 15, 2019

Last Verified

October 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2018-A03070-55

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Perineum; Injury

Clinical Trials on Puncture of the RP6 point

3
Subscribe